BVd Approval Reframes Considerations Around Sequencing BCMA-Targeted Therapies in R/R Myeloma

The multiple myeloma treatment paradigm continues to evolve at a rapid pace, prompting hematologists to rethink longstanding assumptions about when and how to use BCMA-directed therapies. The October 2025 FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma after at least 2 prior lines of therapy—including both a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD)—marks a notable shift in this landscape.¹ Belantamab mafodotin now enters the clinic as part of a triplet regimen, with the potential to influence earlier-line decision-making and later-line treatment sequencing strategies.